FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978586089> ?p ?o ?g. }

• W1978586089 endingPage "442" @default.
• W1978586089 startingPage "431" @default.
• W1978586089 abstract "Saxagliptin, sitagliptin, and vildagliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors widely approved for use in patients with type 2 diabetes. Using a crossover design, the present study compared trough levels of DPP-4 inhibition provided by these agents in a single cohort of patients with type 2 diabetes. This was a randomized, placebo-controlled, open-label, five-period crossover study. Eligible patients were 18–65 years of age, either treatment-naïve or off prior antihyperglycemic agent therapy for at least 6 or 12 weeks (depending on the prior therapy), and had glycated hemoglobin (HbA1C) ≥6.5% and ≤10.0%. In separate study periods, patients received 5 mg saxagliptin q.d. (saxa-5), 100 mg sitagliptin q.d. (sita-100), 50 mg vildagliptin q.d. (vilda-50-q.d.), 50 mg vildagliptin b.i.d. (vilda-50-b.i.d.), or placebo for 5 days. The primary endpoint was trough %DPP-4 inhibition, derived by comparing DPP-4 activity 24 h after the Day-5 morning dose with predose activity in the same period and analyzed using a linear mixed-effects model with fixed-effects terms for treatment and period. Mean (range) baseline HbA1C was 7.4% (6.4–9.0%; N = 22). Least-squares (LS) mean trough %DPP-4 inhibition was 73.5%, 91.7%, 28.9%, 90.6%, and 3.5% after saxa-5, sita-100, vilda-50-q.d., vilda-50-b.i.d., and placebo, respectively. In patients treated with sita-100, the LS-mean difference in trough %DPP-4 inhibition was 18.2% greater than with saxa-5 (p < 0.001), 62.9% greater than with vilda-50-q.d. (p < 0.001), 1.1% greater than with vilda-50-b.i.d. (p = 0.128), and 87.8% greater than with placebo (p < 0.001). Mean %DPP-4 inhibition was nearly maximal at 12 h postdose regardless of active treatment. Thus, these between-group comparisons at trough primarily reflected differences in duration of action. Adverse events reported during the study were transient and mild or moderate in intensity. Once daily treatment with sitagliptin provided trough DPP-4 inhibition significantly greater than saxagliptin or vildagliptin administered once daily, and similar to that provided by vildagliptin administered twice daily." @default.
• W1978586089 created "2016-06-24" @default.
• W1978586089 creator A5002660940 @default.
• W1978586089 creator A5009707371 @default.
• W1978586089 creator A5013234560 @default.
• W1978586089 creator A5016628382 @default.
• W1978586089 creator A5019993254 @default.
• W1978586089 creator A5029797983 @default.
• W1978586089 creator A5060272056 @default.
• W1978586089 creator A5072995863 @default.
• W1978586089 date "2013-10-26" @default.
• W1978586089 modified "2023-10-18" @default.
• W1978586089 title "Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin" @default.
• W1978586089 cites W1981747359 @default.
• W1978586089 cites W1984635769 @default.
• W1978586089 cites W1998673520 @default.
• W1978586089 cites W2012235474 @default.
• W1978586089 cites W2038445107 @default.
• W1978586089 cites W2054185381 @default.
• W1978586089 cites W2064410761 @default.
• W1978586089 cites W2072402715 @default.
• W1978586089 cites W2078126254 @default.
• W1978586089 cites W2103870770 @default.
• W1978586089 cites W2104025164 @default.
• W1978586089 cites W2109688740 @default.
• W1978586089 cites W2112852213 @default.
• W1978586089 cites W2114927834 @default.
• W1978586089 cites W2118609667 @default.
• W1978586089 cites W2134760433 @default.
• W1978586089 cites W2141264129 @default.
• W1978586089 cites W2150859826 @default.
• W1978586089 cites W2161075296 @default.
• W1978586089 cites W4233939878 @default.
• W1978586089 doi "https://doi.org/10.1007/s13300-013-0045-8" @default.
• W1978586089 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3889317" @default.
• W1978586089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24163113" @default.
• W1978586089 hasPublicationYear "2013" @default.
• W1978586089 type Work @default.
• W1978586089 sameAs 1978586089 @default.
• W1978586089 citedByCount "38" @default.
• W1978586089 countsByYear W19785860892014 @default.
• W1978586089 countsByYear W19785860892015 @default.
• W1978586089 countsByYear W19785860892016 @default.
• W1978586089 countsByYear W19785860892017 @default.
• W1978586089 countsByYear W19785860892018 @default.
• W1978586089 countsByYear W19785860892019 @default.
• W1978586089 countsByYear W19785860892020 @default.
• W1978586089 countsByYear W19785860892021 @default.
• W1978586089 countsByYear W19785860892022 @default.
• W1978586089 crossrefType "journal-article" @default.
• W1978586089 hasAuthorship W1978586089A5002660940 @default.
• W1978586089 hasAuthorship W1978586089A5009707371 @default.
• W1978586089 hasAuthorship W1978586089A5013234560 @default.
• W1978586089 hasAuthorship W1978586089A5016628382 @default.
• W1978586089 hasAuthorship W1978586089A5019993254 @default.
• W1978586089 hasAuthorship W1978586089A5029797983 @default.
• W1978586089 hasAuthorship W1978586089A5060272056 @default.
• W1978586089 hasAuthorship W1978586089A5072995863 @default.
• W1978586089 hasBestOaLocation W19785860891 @default.
• W1978586089 hasConcept C126322002 @default.
• W1978586089 hasConcept C134018914 @default.
• W1978586089 hasConcept C142724271 @default.
• W1978586089 hasConcept C204787440 @default.
• W1978586089 hasConcept C27081682 @default.
• W1978586089 hasConcept C2776453732 @default.
• W1978586089 hasConcept C2777180221 @default.
• W1978586089 hasConcept C2777538456 @default.
• W1978586089 hasConcept C2778763485 @default.
• W1978586089 hasConcept C2779284873 @default.
• W1978586089 hasConcept C2780282729 @default.
• W1978586089 hasConcept C555293320 @default.
• W1978586089 hasConcept C71924100 @default.
• W1978586089 hasConcept C87813604 @default.
• W1978586089 hasConcept C90924648 @default.
• W1978586089 hasConcept C98274493 @default.
• W1978586089 hasConceptScore W1978586089C126322002 @default.
• W1978586089 hasConceptScore W1978586089C134018914 @default.
• W1978586089 hasConceptScore W1978586089C142724271 @default.
• W1978586089 hasConceptScore W1978586089C204787440 @default.
• W1978586089 hasConceptScore W1978586089C27081682 @default.
• W1978586089 hasConceptScore W1978586089C2776453732 @default.
• W1978586089 hasConceptScore W1978586089C2777180221 @default.
• W1978586089 hasConceptScore W1978586089C2777538456 @default.
• W1978586089 hasConceptScore W1978586089C2778763485 @default.
• W1978586089 hasConceptScore W1978586089C2779284873 @default.
• W1978586089 hasConceptScore W1978586089C2780282729 @default.
• W1978586089 hasConceptScore W1978586089C555293320 @default.
• W1978586089 hasConceptScore W1978586089C71924100 @default.
• W1978586089 hasConceptScore W1978586089C87813604 @default.
• W1978586089 hasConceptScore W1978586089C90924648 @default.
• W1978586089 hasConceptScore W1978586089C98274493 @default.
• W1978586089 hasIssue "2" @default.
• W1978586089 hasLocation W19785860891 @default.
• W1978586089 hasLocation W19785860892 @default.
• W1978586089 hasLocation W19785860893 @default.
• W1978586089 hasLocation W19785860894 @default.
• W1978586089 hasOpenAccess W1978586089 @default.
• W1978586089 hasPrimaryLocation W19785860891 @default.

• next